Sath Shukla - Feb 3, 2025 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Signature
/s/ Maegan Deare, Attorney-in-Fact for Sath Shukla
Stock symbol
SPRO
Transactions as of
Feb 3, 2025
Transactions value $
-$121,160
Form type
4
Date filed
2/5/2025, 08:31 PM
Previous filing
Aug 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +751K +65.87% $0.00 1.89M Feb 3, 2025 Direct F1
transaction SPRO Common Stock Sale -$4.79K -6.14K -0.32% $0.78 1.89M Feb 5, 2025 Direct F2
transaction SPRO Common Stock Sale -$33.4K -42.8K -2.27% $0.78 1.84M Feb 5, 2025 Direct F3
transaction SPRO Common Stock Sale -$83K -106K -5.77% $0.78 1.74M Feb 5, 2025 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
F2 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.
F3 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023.
F4 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024.